More than a third of US licensing deals this year have involved assets sourced from China, as accelerating growth in such deals attracts investor attention and regulatory scrutiny. This panel will exa …

HSBC’s mid-year report signaled the challenges that many small and mid-sized biotech companies have shared; first financings declined in Q2 of 2025 and entrepreneurs and companies have had to make tou …

Expansion in the target landscape, from TL1A and beyond, has accelerated progress in I&I drug development with multibillion-dollar M&A across the past two years attracting more funding for programs in …

GLP-1 analogs have already rewritten treatment standards and changed patients’ expectations related to obesity.  Evidence continues to build that such pathways can improve cardiometabolic health more …

When companies are not interested in pursuing venture rounds or equity offerings, alternative investment sources can provide critical capital for executing the development projects needed to collect t …

The pace of US biotech IPOs stalled for much of 2025 but reductions in interest rates corelate with an uptick in new offerings as investors reconsider the risks and returns from new medicines in this …

While deal volumes have adjusted following the influx of capital during the pandemic, there has still been significant activity as pharma continues to assess overall strategy and biotech companies see …

As PDUFA VIII negotiations begin and on-going debates on the best way to ensure patients can access medicines continue, biotech executives and investors are seeking clarity on how policy will impact t …